Unlock the potential of mucOne therapeutics
Antibody program available to clinical-stage companies for advancing next-generation cancer therapies
Our humanized mucOne antibodies selectively target tumor-associated aberrant mucin-1 glycoforms, providing a highly precise approach to cancer immunotherapy
Sequence Discovery
High affinity (pM)
Cancer specific
We offer
We offer partnership opportunities with our mucOne antibodies, which are ready for preclinical evaluation in therapeutic applications.
Our validated antibodies specifically target Tn/STn-mucin-1, making them ideal candidates for cancer immunotherapy development.
We provide flexible option agreements tailored to our partners' needs and can supply antibody samples to support preclinical data generation.